Opinion: Coronavirus spending: an expense — or an investment?
In the context of a looming global pandemic, what does it mean to invest in public health?
At a White House meeting this week, President Donald Trump convened key biopharmaceutical industry leaders to advance the development of effective treatments and vaccines to combat the new coronavirus. The industry has responded to this global challenge in unprecedented ways: Moderna identified a promising vaccine candidate just 42 days after the virus was sequenced, the fastest turnaround in history. Gilead’s drug remdesivir, developed (and abandoned) in response to the Ebola outbreak, was resurrected to treat the first U.S. Covid-19 patient and will enter Phase 3 trials in China in a matter of weeks. Other companies, like Regeneron, Inovio, and CureVac, have also jumped into the race.
Read Original Article: Opinion: Coronavirus spending: an expense — or an investment? »
